well-recognized expert in drug discovery & development with proven record of advancing projects from discovery to proof-of-concept in the clinical stage in different fields. Senior Executive in big Pharmas successfully leading the research and development organisations to deliver pipelines. Strong interpersonal skills, extensive experience in working in a matrix environment and highly effective in building collaborative relationships both inside and outside the organisation across the world. Served on Scientific Advisory Boards of governmental bodies, small Biotech companies and financial institutions in Europe, US and Asia. Invited keynote speaker at many drug discovery and development conferences worldwide.
His interests include discovering and developing medicines and the application of translational research principles to drug discovery.
Dr Gromo resigned from Roche in November 2012 and set up his own consulting firm (Gromo Consulting GmbH) focusing primarily on research & development strategies for discovering new medicines.
Dr Gromo received his MD degree and PhD in Clinical and Experimental Hematology at University of Milano, Italy. He completed a residency in Internal Medicine and a Fellowship in Experimental Oncology at University of Pavia, Italy. Eventually, he joined the Internal Medicine Department at San Raffaele Hospital, Milano.
Prior to coming to Hoffmann-La Roche in 1998, he was Assistant Professor (Tenure track), Immunobiology Research Center, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA;
Research Director at Italfarmaco SpA, Milano, Italy;
Medical Advisor-Cardiovascular Division & Director of Biology-Cardiovascular-Lilly Research Laboratories, Indianapolis, Indiana USA.
He has played multiple roles in H-La Roche, including Research Head of Global Cardiovascular & Metabolic Research; Head of Discovery Research, Basel Site; Head of Discovery Research & Head of Non-Clinical Development, Basel Site; Global Head of Metabolic & Vascular Disease Business Unit; and more recently Global Head of Discovery and Development, Metabolic & Vascular Disease Area. Eventually, following the re-assessment of the Discovery leadership situation in China, Dr Gromo was also asked to lead the local R&D organisation in 2011. The goal was to reshape the portfolio (focusing on Virology and Oncology), to further build up the organisation and to hire the new head.
Dr Gromo is Venture Partner at Versant Ventures, a leading healthcare investment firm committed to invest across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics
Dr Gromo serves on the Board of Directors of Piqur (Switzerland), Aprea (Sweden /USA), Northern Biologics (Canada), Nouscom (Switzerland / Italy) and Theracon (Switzerland/France ). He previously served on the Board of Directors of Novira and Annapurna. In 2015, Novira Therapeutics was sold to J&J for an undisclosed amount and in 2016 Annapurna Therapeutics merged with the publicly traded company Avalanche to create Adverum Biotherapeutics
He served/serves as a Scientific Advisor to CSIRO (Australia), Baker Institute (Melbourne, Australia), Integra (Hebrew University, Israel), Momentum Fund (Tel- Aviv University, Israel), BiolineRx (Jerusalem, Israel), Zealand Pharma (Denmark) and to several financial institutions: Aravis (Zurich, Switzerland), Sectoral (Montreal, Canada), Pictet (Geneva, Switzerland), and Pontifax (Tel Aviv, Israel).